Opaleye Management Inc. bought a new position in Fennec Pharmaceuticals Inc (NASDAQ:FENC – Get Rating) in the fourth quarter, Holdings Channel.com reports. The firm bought 272,200 shares of the company’s stock, valued at approximately $2,613,000. Other institutional investors also recently bought and sold shares of the company. UBS Group AG grew its stake in shares […]
Fennec Pharmaceuticals Inc (NASDAQ:FENC – Get Rating) Director Chris A. Rallis sold 1,758 shares of the company’s stock in a transaction dated Friday, May 19th. The shares were sold at an average price of $7.36, for a total transaction of $12,938.88. Following the sale, the director now owns 31,033 shares in the company, valued at […]
Fennec Pharmaceuticals Inc (NASDAQ:FENC – Get Rating) Director Chris A. Rallis sold 1,758 shares of the business’s stock in a transaction that occurred on Friday, May 19th. The stock was sold at an average price of $7.36, for a total value of $12,938.88. Following the sale, the director now owns 31,033 shares of the company’s […]
Fennec Pharmaceuticals Inc (NASDAQ:FENC – Get Rating) Director Chris A. Rallis sold 1,758 shares of the firm’s stock in a transaction dated Friday, May 19th. The shares were sold at an average price of $7.36, for a total transaction of $12,938.88. Following the sale, the director now owns 31,033 shares of the company’s stock, valued […]
Fennec Pharmaceuticals Inc (NASDAQ:FENC – Get Rating) – Stock analysts at Capital One Financial issued their FY2027 EPS estimates for Fennec Pharmaceuticals in a note issued to investors on Thursday, May 11th. Capital One Financial analyst N. Quibria forecasts that the company will post earnings per share of $2.68 for the year. The consensus estimate […]